Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
169 studies found for:    Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions: Drug: Pioglitazone;   Drug: imatinib mesylate
2 Not yet recruiting National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention:
3 Recruiting Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
Conditions: Chronic Myeloid Leukemia;   Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention: Drug: PF-114
4 Recruiting Bosutinib in Elderly Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Bosutinib
5 Recruiting Regional Central Database Recording of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: Practices evaluation
6 Recruiting Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention: Drug: Nilotinib
7 Recruiting Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Condition: Chronic Myelogenous Leukemia
Intervention: Other: Chart Review
8 Recruiting Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
Condition: Chronic Myeloid Leukemia
Intervention: Behavioral: Dasatinib discontinuation
9 Recruiting Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib
10 Recruiting LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients
Condition: Chronic Myeloid Leukemia
Intervention: Other: QoL Survey Booklet
11 Available Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Condition: Chronic Myeloid Leukemia
Intervention: Drug: bosutinib
12 Recruiting Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Imatinib
13 Recruiting Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML)
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Bosutinib;   Behavioral: Phone Calls;   Behavioral: Questionnaires
14 Not yet recruiting Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: blood sampling
15 Recruiting Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)
Condition: Chronic Myeloid Leukemia
Intervention: Other: biological samples
16 Not yet recruiting Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib
17 Recruiting Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Peginterferon α2b;   Drug: Nilotinib
18 Recruiting Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
19 Recruiting Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib
20 Recruiting A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Omacetaxine mepesuccinate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.